1. Pink Sheet
  2. >>R&D

Patient-Focused Drug Development Events May Be Giving Way To Small, Private Meetings With FDA

 
• By Derrick Gingery

Patient listening sessions, which are easier to schedule, have overtaken traditional patient-focused drug development meetings in terms of volume, although US FDA’s data may be incomplete.

Small meeting
The private, and smaller, patient listening sessions can be scheduled faster than traditional patient-focused drug development meetings. • Source: Shutterstock

Small private meetings with US Food and Drug Administration staff are now more widely used than larger public events to gather first-hand patient information to aid regulatory decisions.

Patient listening sessions (behind-closed-doors gatherings of a small group of patients and advocates to discuss experiences and unmet needs with FDA staff) outnumber FDA- and externally-led patient-focused drug development (PFDD)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

User Fee-Funded Staff Would Drop In FY 2026 US FDA Budget

 
• By Derrick Gingery

The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.

Canada Cuts Red Tape With Single Ethics Review For Trials

 
• By Neena Brizmohun

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.